KLRC1 and acute lymphoblastic leukemia: In line with this, blockade of the NKG2A co-receptor CD94 has been shown to enhance the response of highly activated NKG2A+ NK cells against a cell line transgenically expressing very high levels of HLA-E but not against primary ALL cells expressing an intermediate level of HLA-E (25).